Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial
収録刊行物
-
- The Lancet Oncology
-
The Lancet Oncology 17 (8), 1047-1060, 2016-08
Elsevier BV